目的 觀察多巴絲肼片聯(lián)合依達(dá)拉奉治療血管性帕金森綜合征的臨床療效，以期為血管性帕金森綜合征的治療提供借鑒。方法 以入榆林市星元醫(yī)院就診的血管性帕金森綜合征患者為研究治療對(duì)象，將患者隨機(jī)分為觀察組與對(duì)照組，對(duì)照組以多巴絲肼片治療，觀察組在對(duì)照組基礎(chǔ)上予以依達(dá)拉奉治療，治療20 d，觀察治療前后臨床癥狀與體征，采用帕金森病評(píng)定量表（UPDRS）評(píng)價(jià)臨床療效。結(jié)果 共搜集患者60例，每組各30例，各組在年齡、性別、分級(jí)、UPDRS評(píng)分、危險(xiǎn)因素等方面具有可比性。觀察組患者顯效17例，有效11例，無效2例，總有效率為93.33%；對(duì)照組患者顯效12例，有效10例，無效8例，總有效率為73.33%。有效率比較，差異有顯著性意義（P<0.05），說明觀察組有效率明顯高于對(duì)照組；兩組患者治療后的精神情緒行為、日常生活活動(dòng)評(píng)分和運(yùn)動(dòng)功能評(píng)分較治療前均有所降低（P<0.05），治療后患者日常生活、行為精神情緒、運(yùn)動(dòng)檢查等UPDRS評(píng)分的比較，差異有顯著性（P<0.05），觀察組UPDRS評(píng)分改善明顯高于對(duì)照組。所有患者治療前后一般體格檢查及血、尿常規(guī)，肝腎功能，心電圖均在正常范圍內(nèi)，未出現(xiàn)嚴(yán)重不良反應(yīng)。結(jié)論 依達(dá)拉奉聯(lián)合多巴絲肼片治療血管性帕金森綜合征的臨床療效要優(yōu)于單獨(dú)使用多巴絲肼片，且具有良好的安全性。

Objective To investigate the clinical efficacy of levodopa and benserazide hydrochloride tablets combined with edaravone in treatment of vascular parkinsonism, in order to provide the treatment reference on vascular parkinsonism. Methods The patients with vascular parkinsonism in Xingyuan Hospital of Yulin City were chosen and randomly divided into observation group and control group. The control group was given levodopa and benserazide hydrochloride tablets, the observation group was given edaravone on the base of control group. The treatment group and control group were all treated for 20 d, the clinical symptoms and signs of two groups were observed, and the clinical efficacy was evaluated by unified Parkinson's disease rating scale (UPDRS). Results The age, sex, grade, UPDRS score, and risk factors of two groups had no significant difference. There were 17 cases with excellent efficacy in observation group, 11 cases effective, 2 cases valid, and the total efficacy was 93.33%, while the control group were 12 cases, 10 cases, 8 cases, and 73.33%.The effective rates of two groups had significant difference (P<0.05). Compared with before treatment, the emotional behavior score, movement function score, and daily life activities of two groups were obvious decreased (P<0.05). Compared with before treatment, the daily life, behavior, mental emotional, motion checking UPDRS score had significant difference (P<0.05). The UPDRS score of observation group was higher than the control group. The blood and urine routine, hepatic and renal function, and electrocardiogram of two groups before and after treatment were all in normal range, without serve adverse reaction. Conclusion Levodopa and benserazide hydrochloride tablets combined with edaravone in treatment of vascular parkinsonism was superior to levodopa and benserazide hydrochloride, with good safety.